MS Flashcards

1
Q

Multiple Sclerosis is

A

chronic inflammatory, autoimmune, demyelinating disease of CNS

An abnormality in the immune response thatresults in an attack on the individuals own neural tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common theory for MS

A

environmental trigger, probably a virus induces a delayed autoimmune attack on a genetically susceptible individual.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Relapsing –remitting (RRMS)

A

relapses with full recovery or some remaining neurological symptoms and residual deficits. Then New attack

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MS New Attack

A

New symptoms must last at least 24 hours and be separate from other symptoms by at least 30 days to qualify as a new attack

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Primary-progressive (PPMS)

A

progression from the onset without remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Secondary-progressive ( SPMS)

A

initial relapsing-remitting course followed by progression at a variable rate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Progressive-relapsing (PRMS)

A

progressive disease from onset but with clear acute relapses that may or may not have some recovery or remission.
Common in people who develop the disease after 40.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

General clinical mainifestation of MS pt 1

A
Heat sensitivity
Fatigue
Gait disturbance
Weakness, mild paresis to total paralysis
Spasticity
Balance and coordination
Speech and swallowing dysfunction
BB dysfunctipon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

General clinical manifestations of MS pt 2

A
Pain
Parenthesis and other sensory changes
Visual disturbances
Cog problems
Tremors
Depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

McDonald Criteria

A

For dx of MS

> /= 2 attacks and >/= 2 clinical evidence of lesion = MS

> /= 2 attacks and 1 clinical evidence of lesion and clear evidence of prior attack involving lesion in different location = MS

Other criteria gets more complicated. Just know big idea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

McDonald- person who has 1 year steady disease progression needs

A

At least 2 of following:
>/= MS typical T2 lesion
>/= 2 T2 SC lesion
CSF oligioclonal bands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MS cure

A

None

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MS treatment focused on

A

Immune modulation - slowing activated immune system from getting to central fibers slows the processes of demyelination in MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Phase 1 MS treatment (acute)

A

Corticosteroids - reduce inflammation and shorten duration of flare ups

Plasma exchange - effective for people who have sudden, severe attacks of MS related disability but don’t benefit from high dose corticosteroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Plasma exchange most helpful

A

In MS pts who had mild disability before attack

No proven benefit beyond 3 mo from onset of neuro symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MS tx phase 2

A

Med used to modify the course of disease progression as well as ongoing management of symptoms of MS

17
Q

MS beta infernos - subacute

A

Approved only for people who have relapsing forms
Reduce frequency and severity of flare ups

Prevent disability
Recommended for people who have more than one MS attack/year and for those who dont recover well from flare ups

18
Q

MS - ABC drugs

A

A - interferon beta 1a (avonex)
B- interferon beta 1b (betaseron)
C - glatiramer acetate (copaxone)

19
Q

MS - corticosteroid plus ACTH

A

Shortened recovery period after acute attack

20
Q

MS - avonex and refib (interferon beta 1a)

A

Slow down immune response -> reduce inflammation, swelling, rapid proliferation of T and B cells, block activated T cells from crossing BBB and damaging myelin

21
Q

MS betaseron

A

Higher dose of interferon eliciting a movie potent reponse

22
Q

MS copaxone

A

Immunomodulator
Decoy to clot T cell receptors
Fools immune system to decrease attack on myelin

23
Q

MS Mitoxantrone

A

Immunosuppressant
Modify replacing and secondary progressive MS
Only drug approved for tx of secondary progressive MS

24
Q

Natalizumab

A

Monoclonal antibody that prevents immune cells from moving from blood into CNS

25
MS Fingolimod
New oral immunomodulating agent under eval for tax of relapsing remitting MS
26
MS depression
Meds and sleep aid Clonazepam used at night to aid in sleep intation and decrease spasm
27
Ms and botulism
Focal injections to decrease spastic uncles
28
MS PT manage
``` Intervention to manage - fatigue, weakness, spasticity, sensory loss Balance and coordination training Improve speech Transfer and gait terminating W/c training Equipment/orthotic eval Referral for psychological issues ```
29
Average frequency of attacks of MS
1 a year
30
MS attacks tend to be more frequent in
Early stages, | Become less frequent in later years
31
MS strongest predictor of outcome
MRI Scans w/ > 10 lesions - predict individuals will need cane w/in same time frame Change in lesion load w/in first year is also a negative predictor of outcome
32
MS onset at young age
May be more favorable than onset after 40 which is associated w/ PRMS
33
MS one f the most important prognostic factors
Neuro findings at 5 years Sig pyramidal and cerebellar signs w/ involvement of multiple sites associated w/ poorer prognosis and a more severe disability
34
MS and life expectancy
Reduced by a modest amount 74% surviving after 25 yrs after onset Only small percent able to work 10 years after dx 15 years, 50% need AD 20 yrs, 50% W/c
35
MS Death rate in persons who are unable to walk or stand
More than 4x that in person same age w/out MS